Azzad Asset Management Inc. ADV Buys 895 Shares of AstraZeneca PLC (NASDAQ:AZN)

Azzad Asset Management Inc. ADV raised its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,127 shares of the company’s stock after acquiring an additional 895 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in AstraZeneca were worth $4,640,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. New England Research & Management Inc. boosted its position in shares of AstraZeneca by 159.3% in the 1st quarter. New England Research & Management Inc. now owns 15,950 shares of the company’s stock worth $1,172,000 after purchasing an additional 9,800 shares in the last quarter. Elevation Point Wealth Partners LLC boosted its position in shares of AstraZeneca by 23.3% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 55,075 shares of the company’s stock worth $4,048,000 after purchasing an additional 10,422 shares in the last quarter. Stanley Laman Group Ltd. boosted its position in shares of AstraZeneca by 19.5% in the 1st quarter. Stanley Laman Group Ltd. now owns 58,849 shares of the company’s stock worth $4,325,000 after purchasing an additional 9,614 shares in the last quarter. Compagnie Lombard Odier SCmA purchased a new position in AstraZeneca in the 1st quarter worth $175,000. Finally, Simon Quick Advisors LLC raised its stake in AstraZeneca by 42.8% in the 1st quarter. Simon Quick Advisors LLC now owns 7,969 shares of the company’s stock worth $586,000 after acquiring an additional 2,390 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ:AZN opened at $74.42 on Friday. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The stock has a 50 day moving average of $69.81 and a two-hundred day moving average of $70.26. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm has a market cap of $230.80 billion, a P/E ratio of 32.93, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.06 EPS. On average, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, BNP Paribas began coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.